

## Supplemental Digital Content 1

Characteristics of ART patients with VL&gt;1,000 copies/mL successfully genotyped.

Patient ID	Treatment	ART duration (in months)	VL m2000rt assay (copies/mL)	VL G2 Generic assay (copies/mL)	Subtype*	NRTI** Mutations	NNRTI*** Mutations
HES08	D4T/3TC/EFV	20	ND	1 217	CRF25_cpx	-	-
VIR29	D4T/3TC/EFV	28	ND	1 355	C	-	K103N
VIR108	D4T/3TC/EFV	63	ND	1 575	A	-	-
BEN02	D4T/3TC/NVP	17	ND	1 720	D	-	-
RUB07	D4T/3TC/NVP	36	ND	1 827	G	-	-
HES06	D4T/3TC/EFV	35	ND	2 115	D	V118I	V179D
RUB01	AZT/3TC/EFV	29	ND	2 437	A	-	-
HES21	D4T/3TC/EFV	13	ND	3 308	H	-	-
HES05	D4T/3TC/NVP	51	ND	3 403	URF	-	-
MAN02	D4T/3TC/EFV	34	ND	3 906	URF	-	K103N
HES11	D4T/3TC/EFV	42	ND	4 148	D	-	-
BEN14	D4T/3TC/EFV	20	ND	5 960	D	-	-
VIR17	AZT/3TC/EFV	20	ND	6 727	URF	-	-
VIR88	AZT/3TC/EFV	14	ND	7 676	C	-	-
VIR102	AZT/3TC/EFV	15	ND	7 985	D	-	-
MBI11	D4T/3TC/EFV	19	1 223	450	A1		
VIR106	AZT/3TC/EFV	17	1 496	9 148	A	-	-
MAT06	D4T/3TC/EFV	21	2 412	1 196	D	V75I	-
VIR10	D4T/3TC/EFV	30	2 714	2 477	A	-	-
ALO07	D4T/3TC/NVP	47	4 407	3 428	A	-	-
MAK23	D4T/3TC/NVP	50	4 437	2 810	A	M184V	K101E, V179I, G190A
MAB06	D4T/3TC/EFV	39	8 682	902	C	M184V, T215Y	K103KN, G190A
VIR32	D4T/3TC/EFV	24	9 572	26 715	A	M41L, D67N, K70R, M184V, T215Y	A98G, V106I, V179I, Y188L
VIR92	D4T/3TC/EFV	28	12 541	5 796	A	M184V	K103N
RUT03	AZT/3TC/EFV	20	13 914	3 434	A	-	-
RUB08	AZT/3TC/EFV	15	14 911	2 585	CRF25_cpx	M184V	K103N
MAN05	D4T/3TC/EFV	23	15 761	5 997	URF	V118I	V106I, V179E
VIR09	D4T/3TC/NVP	29	21 675	3 627	A	M184IMV	A98AG, V179I, G190AG
MAK 01	D4T/3TC/EFV	29	22 439	3 029	A	-	K103KN
BEN15	D4T/3TC/NVP	37	24 895	5 603	URF	M184V	K103N
VIR105	AZT/3TC/NVP	12	26 681	2 941	G	-	-
MBI12	D4T/3TC/EFV	30	28 670	4 524	D	-	-
MAT05	D4T/3TC/NVP	59	30 858	11 420	URF	-	-
VIR06	D4T/3TC/EFV	36	34 714	3 969	URF	M184V	K103N, Y181C
MBI03	AZT/3TC/EFV	18	35 937	7 883	C	M184V	V90I, E138Q, G190A
ALO03	D4T/3TC/NVP	50	54 454	45 113	A1	-	-
RUT07	AZT/3TC/EFV	33	65 198	4 968	CRF25_cpx	M184V	K101KR, K103N, Y181C, H221Y
RUB14	D4T/3TC/EFV	28	92 180	105 332	D	M184MV	K103KN, G190AG
MAG15	D4T/3TC/NVP	31	95 954	68 629	A	T69N, M184V	Y181C, H221Y
VIR111	AZT/3TC/EFV	24	96 092	8 759	A	M184V	K103N
MAK13	D4T/3TC/EFV	36	129 429	7 565	D	M184V, T215ST	K103N, Y181C
HES30	D4T/3TC/NVP	24	141 615	29 033	A	-	-
VIR21	D4T/3TC/EFV	47	156 045	25 837	A	M184V, T215Y	G190A
MBI17	D4T/3TC/EFV	38	159 798	28 357	D	-	-
MAK16	D4T/3TC/NVP	32	327 424	46 932	G	M184V	K103N
MAB04	AZT/3TC/EFV	48	359 949	92 189	A	M184V	K103N, V108IV
MAT08	D4T/3TC/EFV	28	529 883	373 950	A	-	-
MAK26	AZT/3TC/NVP	50	569 842	277 052	A	M184V, T215NSTY	K103KNRS, G190A
ALO14	D4T/3TC/NVP	61	645 505	62 744	URF	-	-
HES17	D4T/3TC/NVP	14	711 557	211 883	A	-	K103N
VIR93	AZT/3TC/EFV	13	912 645	99 239	A	-	V106AV, G190AG
RUT04	D4TC/3TC/EFV	50	1 392 492	483 080	A1	M184V, T215NSTY	A98G, V179I, G190A
VIR61	D4T/3TC/NVP	44	1 441 561	976 086	A	M184V	K103N
MAT03	D4T/3TC/NVP	58	2 688 793	394 963	URF	M184V	K103N, K238T
VIR26	AZT/3TC/EFV	15	6 525 105	855 176	A	-	A98S

ND: Not Detected

Shadowed lines correspond to the 27 patients harboring mutations inducing resistance to the drugs of the current first line ART..

Subtype\*: HIV-1 strains were classified using phylogenetic analysis (maximum likelihood implemented with HIV-1 subtype references and circulating recombinant forms (CRFs) sequences). Recombination analysis using the Bootscan tool were conducted to identify and confirm the unknown recombinant forms (URFs).

NRTI\*\*: nucleoside reverse transcriptase-inhibitors; NNRTI\*\*\*: non-nucleoside reverse transcriptase-inhibitors